Coverage
Filings
| Filing | Date |
|---|---|
| Director/PDMR Shareholding | 15 Jan 2025 |
| Director/PDMR Shareholding | 14 Jan 2025 |
| GSK enters agreement to acquire IDRx, Inc. | 13 Jan 2025 |
| Director/PDMR Shareholding | 13 Jan 2025 |
| Shingrix fully liquid accepted for US FDA review | 10 Jan 2025 |
| GSK ADC gets FDA breakthrough therapy designation | 7 Jan 2025 |
| GSK’s Nucala approved in China for use in CRSwNP | 3 Jan 2025 |
| Total Voting Rights |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 2 Jan 2025 |
| Director/PDMR Shareholding | 23 Dec 2024 |
| Headline results from phase III FIRST trial | 20 Dec 2024 |
| Block Listing Application | 20 Dec 2024 |
| Jemperli receives positive CHMP opinion | 16 Dec 2024 |